Elisabetta Bonzano MD, PhD· @to_be_elizabeth · X·· 2 天前评分70
正文 · 机器翻译
📌 快速口头报告：乳腺癌，早期
✨DESTINY-Breast05 的患者报告结局：高危 HER2 阳性 eBC 患者使用 T-DXd 与 T-DM1 时的 HRQoL
#ESMO26 🇪🇸 @OncoAlert #OncoAlertAF
235 浏览 · 6 赞 · 5 转发 · 0 回复
会议摘要
539RO按 Rapid oral: Breast cancer, early stage 对上
Patient-reported outcomes (PROs) from DESTINY-Breast05: Health-related quality of life (HRQoL) with trastuzumab Deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (Pts) with high-risk HER2-positive early breast cancer (eBC)
https://esmocongress.esmo.org来源：Elisabetta Bonzano MD, PhD · x.com